Lepu Medical Technology (Beijing) reported its first-quarter 2024 financial results, showing revenue of CN¥1.92 billion, a 21% decrease from the same period last year. Net income was CN¥481.9 million, down 19% from the same period in 2023. Despite the decline in revenue and net income, the company’s profit margin remained consistent at 25%. Earnings per share (EPS) decreased to CN¥0.26 from CN¥0.32 in the first quarter of 2023.
The company’s performance fell short of analyst expectations, with revenue missing estimates by 13% and EPS also falling short by 4.3%. Despite this, Lepu Medical Technology (Beijing) is projected to grow by an average of 19% annually over the next three years compared to a forecasted growth of 19% for the Medical Equipment industry in China.
While the company’s shares have decreased by 1.0% in the past week, there may still be risks associated with investing in Lepu Medical Technology (Beijing). It is crucial to consider potential warning signs that could impact the company’s valuation and financial health for a comprehensive analysis. To access additional information on fair value estimates, risks, dividends, insider transactions, and financial health, investors can consult Simply Wall St for unbiased long-term analysis based on fundamental data but not including recent company announcements or qualitative information.
Investors should always conduct their own research and take into account their own objectives and financial situation before making investment decisions.
Feedback on the article or concerns about its content can be directed directly to Simply Wall St’s editorial team. The article provides commentary based on historical data and analyst forecasts and should not be considered financial advice.
